

EXHIBIT B

<u>Mylan Product</u>	<u>Mylan Market Share According to Mylan</u>	<u>Kirkland's Adverse Representation</u>	<u>Source</u>
Modafinil (generic Provigil)	"Cephalon's annual U.S. sales of Provigil® exceed \$1.1 Billion. If permitted to launch immediately, Mylan expects to capture a substantial percentage of modafinil [generic Provigil®] product sales."	Teva Pharmaceuticals USA, Inc.; Cephalon, Inc.	Mylan Pharms. v. FDA, 12-CV-524, (D.D.C. April 5, 2012), Dkt. 5, ¶ 4 (Decl. of Anthony Mauro, Pres. Mylan Pharms. Inc.) ¹
Celecoxib (generic Celebrex)	"If the Court does not act quickly, [Mylan] will be irreparably harmed by the loss of tens of millions of dollars and significant lost market share, important customers, and reputation within the generic drug industry."	Teva Pharmaceuticals USA, Inc.	Mylan Pharms. Inc. v. FDA, 14-CV-00075, (N.D. W.Va.), Dkt. 22, pp. 4–5 (Mylan's Mot. for Prelim. Injunction) ²
Glatiramer acetate (generic Copaxone)	"Given that Copaxone® is a multibillion dollar drug for Teva, if Mylan were barred from launching its glatiramer acetate product, the lost market opportunity for Mylan could easily amount to hundreds of millions of dollars."	Teva Pharmaceutical Industries, Ltd.; Teva Neuroscience, Inc.	Teva Pharm. Indus., Ltd. v. Sebelius, 14-CV-00786, (D.D.C.) Dkt. 23-1, ¶ 12 (Decl. of Anthony Mauro, Pres. Mylan Pharms. Inc.) ³
Extended-release paroxetine (generic Paxil CR)	Judgement of \$121 million awarded to Mylan Inc. after a finding that GlaxoSmithKline breached a contract granting Mylan Inc. the exclusive right to make, sell, and import generic extended-release paroxetine.	SmithKline Beecham Corp., n/k/a GlaxoSmithKline LLC	Mylan Inc. v. SmithKline Beecham Corp., Case No. 12-1539, (3d Cir.), ⁴ on remand 10-CV-4809, Dkts. 389, 428
Valsartan (generic Diovan)	"Mylan alleges that absent injunctive relief [Mylan Labs] will suffer substantial 'irretrievable' financial losses, including a loss in first-year sales of up to \$44.55 million, or 'perhaps more.'"	Ranbaxy Laboratories, Inc.	Mylan Labs. Ltd. v. F.D.A., 12-CV-1637, (D.D.C.), Dkt. 17, p. 27–28, (Order on Mylan's Mot. for Prelim. Injunction) ⁵

¹ See Exh. 1 to Declaration of Michael D. Shumsky (Dkt. 40)

² See Exh. A to Defendant's Memorandum in Opposition to Plaintiffs' Motion for Preliminary Injunction (Dkt. 32); Exh. 2 to Declaration of Michael D. Shumsky (Dkt. 40)

³ See Exh. A to Defendant's Memorandum in Opposition to Plaintiffs' Motion for Preliminary Injunction (Dkt. 32); Exh. 4 to Declaration of Michael D. Shumsky (Dkt. 40)

⁴ See Exh. A to Defendant's Memorandum in Opposition to Plaintiffs' Motion for Preliminary Injunction (Dkt. 32)

⁵ See Exh. A to Defendant's Memorandum in Opposition to Plaintiffs' Motion for Preliminary Injunction (Dkt. 32)